The Application of Robotics to Aseptic Environmental Surface Monitoring - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Application of Robotics to Aseptic Environmental Surface Monitoring
This article presents a study of an aseptic environmental monitoring system for surface contamination at critical areas using a robot.


Pharmaceutical Technology



Figure 6
Complete recovery of M. luteus could not be achieved in these experiments, which is not surprising. However, the robotic sampling operation could achieve much better recovery of M. luteus than could manual sampling. This better result could be attributed to the robot's more precise control over sampling speed, pressure, and area (5) (see Figures 3–7).

Conclusion


Figure 7
The experimental data suggest that the operating parameters of robotic surface sampling shown in Figure 7 result in the best rates of recovery. However, further investigation will be required to determine whether higher recovery rates can be obtained with other robotic sampling parameters. The authors will investigate both the influence of robotic sampling parameters as well as other variables such as swab-tip composition, flexibility of the swab's rod, and recovery media. It is significant that the recovery rates observed with the robotic swab method were in many cases three to fourfold higher than those that resulted from manual swabbing under otherwise identical experimental conditions. These results indicate that robotic sampling has the potential to improve the limit of detection of surface monitoring and also to reduce variability.

The authors believe the automated approach to monitoring reduces the likelihood of false-positive results, although they did not attempt to quantify this benefit. Of course, because the robotic sampling parameters are variable and user-selectable, it will be possible for users to define sampling conditions that are optimal for their particular application (6). The authors are also aware that the robotic surface-sampling method may afford advantages in terms of chemical recovery. This means that a robot installed in an isolator for microbiological sampling could be used to assess cleaning effectiveness as well. This, of course, would depend upon the location of the robot within an enclosure or RABS environment.

Mayumi Maruyama, Tomoo Matsuoka, and Motonari Deguchi work in the Microbial Control Department at Shibuya Kogyo Co., Ltd. in Kanazawa, Japan. James E. Akers* is the president of Akers Kennedy & Associates, PO Box 22562, Kansas City, MO 64113,
.

*To whom all correspondence should be addressed.

References

1. J.E. Akers and Y. Oshima, "PAsepT, Aseptic Vial Filling Processing Based on Principles of PAT," in Presentation at the ISPE Annual Conference (San Antonio, TX, 2004).

2. M. Deguchi, et al, "Development of an Advanced High Speed Aseptic Filling System," in Proceedings of the PDA International Congress, (Kyoto, Japan, 2001).

3. B. Ljungvist, B. Reinmüller, and R. Nydahl, "Microbiological Assessment in Clean Rooms for Aseptic Processing," J. R3 Nordic 23(3), 7-10, 1995.

4. J.E. Akers, "Environmental Monitoring and Control: Proposed Standards, Current Practices and Future Directions," J. Pharm Sci. Techn. 51(1), 36-47, 1996.

5. NASA, NASA Handbook for Biological Engineers (National Aeronautics and Space Administration, Washington, DC, 1971).

6. J. Levchuk, "FDA's Perspectives on Aseptic Process Validation," in Proceedings of the Third Annual GMP by the Sea Conference (University of Rhode Island School of Pharmacy, Kingston, RI, 2003).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here